IDiyas

For the Inventor, By the Inventor

Rochester, NY, United States of America

Vaccinex, Inc.


USPTO Granted Patents = 51



Trademarks = 3

Forward Citations = 371

Loading Chart...
Loading Chart...

53 inventors (with patents filed for the assignee):

goldMedal Ernest S Smith (42 out of 45 patents)

silverMedal Maurice Zauderer (27 out of 40 patents)

bronzeMedal Mark Paris (12 out of 12 patents)

4.  Elizabeth E Evans (11 out of 17 patents)

5.  Terrence Lee Fisher (9 out of 19 patents)

6.  Renee A Kirk (7 out of 7 patents)

7.  Maria G M Scrivens (6 out of 6 patents)

8.  Angelica A Cornelison (6 out of 6 patents)

9.  William J Bowers (4 out of 9 patents)

10.  Alan Jonason (4 out of 4 patents)

11.  Leslie A Croy (4 out of 4 patents)

12.  Ekaterina Klimatcheva (3 out of 3 patents)

13.  Tracy Pandina (3 out of 3 patents)

14.  Leslie A Balch (3 out of 3 patents)

15.  Jean-Pierre Mach (2 out of 6 patents)


Core Competencies:
Semaphorin-4D
Anti-CD100 Antibodies
CXCL13 Antibodies
Immune Modulating Therapy
Neurodegenerative Disorders
Poxvirus Extracellular Virions
Polynucleotide Libraries
Tumor Growth Inhibition
Atherosclerosis Treatment
NKT Cell Modulation
Epigenetic Modulating Agents
Monoclonal Antibodies

51 patents:

1. 12201719 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2025-01-21),
2. 12070500 - Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis (2024-08-27),
3. 12006365 - Human anti-semaphorin 4D antibody (2024-06-11),
4. 12006364 - Anti-CD100 antibodies and methods for using the same (2024-06-11),
5. 11981730 - Anti-CXCL13 antibodies and methods of using the same (2024-05-14),
6. 11976383 - Integral membrane protein display on poxvirus extracellular enveloped virions (2024-05-07),
7. 11859000 - Anti-CCR8 antibodies and uses thereof (2024-01-02),
8. 11660330 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2023-05-30),
9. 11597765 - Use of semaphorin-4D binding molecules for the treatment of Rett syndrome (2023-03-07),
10. 11572408 - Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent (2023-02-07),
11. 11534488 - Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability (2022-12-27),
12. 11427634 - Human anti-semaphorin 4D antibody (2022-08-30),
13. 11274149 - Anti-CD100 antibodies and methods for using the same (2022-03-15),
14. 11078295 - Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases (2021-08-03),
15. 10870707 - Integral membrane protein display on poxvirus extracellular enveloped virions (2020-12-22),
Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel therapeutic antibodies to treat a wide range of diseases, including cancer and neurodegenerative disorders. With its proprietary platform called ActivMAb®, Vaccinex discovers and optimizes fully human antibodies with unique mechanisms of action. The company is dedicated to improving patient outcomes by advancing its pipeline of therapeutic candidates through rigorous scientific research and clinical trials.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

...
51 Patents

#20 in Rochester, NY

#380 in New York

#6,650 in US

#13,352 in the World

...
Rochester, NY, United States of America

Vaccinex, Inc.

Forward Citations = 371

53 inventors:

goldMedal Ernest S Smith (42 out of 45 patents)

silverMedal Maurice Zauderer (27 out of 40 patents)

bronzeMedal Mark Paris (12 out of 12 patents)

4.  Elizabeth E Evans (11 out of 17 patents)

5.  Terrence Lee Fisher (9 out of 19 patents)

Please report any incorrect information to support@idiyas.com
Loading…